REFERENCES
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of
hyperglycemia in type 2 diabetes: a patient-centered approach:
position statement of the American Diabetes Association (ADA) and the
European Association for the Study of Diabetes (EASD). Diabetes Care
2012;35:1364-1379.
- Cahn A, Miccoli R, Dardano A, Del Prato S. New forms of insulin and
insulin therapies for the treatment of type 2 diabetes. Lancet
Diabetes Endocrinol 2015;3:638-652.
- Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The
morphology of cirrhosis: recommendations on definition, nomenclature,
and classification by a working group sponsored by the World Health
Organization. J Clin Pathol 1978;31:395-414.
- Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G.
Pathogenesis of glucose intolerance and diabetes mellitus in
cirrhosis. Hepatology 1994;19:616-627.
- Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes
mellitus in patients with cirrhosis: clinical implications and
management. Liver Int 2016;36:936-948.
- Gentile S, Guarino G, Strollo F, et al. Lispro insulin in people with
non-alcoholic liver cirrhosis and type 2 diabetes mellitus. Diabetes
Res Clin Pract 2016;113:179-186.
- Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular
risks. Diabetes Care 2011;34:S132-S137.
- Herman ME, O’Keefe JH, Bell DSH, Schwartz SS. Insulin therapy
increases cardiovascular risk in type 2 diabetes. Prog Cardiovasc Dis
2017;60:422-434.
- Holden SE, Jenkins-Jones S, Morgan CL, Schernthaner G, Currie CJ.
Glucose-lowering with exogenous insulin monotherapy in type 2
diabetes: dose association with all-cause mortality, cardiovascular
events and cancer. Diabetes Obes Metab 2015;17:350-362.
- Donadon V, Balbi M, Zanette G. Hyperinsulinemia and risk for
hepatocellular carcinoma in patients with chronic liver diseases and
type 2 diabetes mellitus. Expert Rev Gastroenterol Hepatol
2009;3:465-467.
- Cheng TM. Taiwan’s new national health insurance program: genesis and
experience so far. Health Aff (Millwood) 2003;22:61-76.
- Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes
diagnosis in health insurance claims data in Taiwan. J Formos Med
Assoc 2005;104:157-163.
- Nehra MS, Ma Y, Clark C, Amarasingham R, Rockey DC, Singal AG. Use of
administrative claims data for identifying patients with cirrhosis. J
Clin Gastroenterol 2013;47:e50-e54.
- Mukerji AN, Patel V, Jain A. Improving survival in decompensated
cirrhosis. Int J Hepatol 2012;2012:318627.
- Meduru P, Helmer D, Rajan M, Tseng CL, Pogach L, Sambamoorthi U.
Chronic illness with complexity: implications for performance
measurement of optimal glycemic control. J Gen Intern Med
2007;22:408-418.
- Young BA, Lin E, Von Korff M, et al. Diabetes complications severity
index and risk of mortality, hospitalization, and health care
utilization. Am J Manag Care 2008;14:15-23.
- D’Agostino RB, Jr. Propensity score methods for bias reduction in the
comparison of a treatment to a non-randomized control group. Stat Med
1998;17(19):2265-2281.
- Iezzoni LI. Risk adjustment for measuring healthcare outcomes.
Chicago: Health Administration Press, 1997.
- Elkrief L, Chouinard P, Bendersky N, et al. Diabetes mellitus is an
independent prognostic factor for major liver related outcomes in
patients with cirrhosis and chronic hepatitis C. Hepatology
(Baltimore, MD) 2014;60:823-831.
- Gentile S, Turco S, Guarino G, et al. Effect of treatment with
acarbose and insulin in patients with non-insulin-dependent diabetes
mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes
Metab 2001;3:33-40.
- Fleming KM, Aithal GP, Card TR, West J. All-cause mortality in people
with cirrhosis compared with the general population: a
population-based cohort study. Liver Int 2012;32:79-84.
- Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA,
Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors,
pathophysiology, clinical implications and management. World J
Gastroenterol 2009;15:280-288.
- Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA. Insulin use
and increased risk of mortality in type 2 diabetes: a cohort study.
Diabetes Obes Metab 2010;12:47-53.
- Marchesini G, Ronchi M, Forlani G, et al. Cardiovascular disease in
cirrhosis—a point-prevalence study in relation to glucose tolerance.
Am J Gastroenterol 1999;94:655-662.
- Cao W, Ning J, Yang X, Liu Z. Excess exposure to insulin is the
primary cause of insulin resistance and its associated
atherosclerosis. Curr Mol Pharmacol 2011;4:154-166.
- Hsiang JC, Gane EJ, Bai WW, Gerred SJ. Type 2 diabetes: a risk factor
for liver mortality and complications in hepatitis B cirrhosis
patients. J Gastroenterol Hepatol 2015;30:591-599.
- Ferrannini E, Cushman WC. Diabetes and hypertension: the bad
companions. Lancet 2012;380:601-610.
- Schroeder CA Jr., Chen YL, Messina EJ. Inhibition of NO synthesis or
endothelium removal reveals a vasoconstrictor effect of insulin on
isolated arterioles. Am J Physiol 1999;276:H815-H820.
- Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in
normal and insulin-resistant states. Cold Spring Harb Perspect Biol
2014;6:a009191.
- Mathur A, Pandey VK, Kakkar P. PHLPP: a putative cellular target
during insulin resistance and type 2 diabetes. J Endocrinol
2017;233:R185-R198.
Figure 1. Flowchart of patient selection for this study.
Figure 2. Cumulative incidence curves of (A) all-cause
mortality, (B) decompensated cirrhosis, (C) hepatic failure, and (D)
major adverse cardiovascular events (MACE) between insulin users and
nonusers with diabetes and compensated cirrhosis.
TABLE 1 Baseline characteristics of insulin users and nonusers
with type 2 diabetes mellitus and compensated liver cirrhosis